Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
Conditions
PARKINSON DISEASE (Disorder) · Apathy · Safety
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Medical Center "Galileo" OOD, Pleven, Bulgaria
Contact: Study coordinator (Plamen Bozhinov, Prof.)First University Multiprofile Hospital for Active Treatment MHAT - Neurology Clinic, Sofia, Bulgaria
Contact: Study coordinator (PI Prof. Dimitar Maslarov)University Multiprofile Hospital for Active Treatment "Alexandrovska" EAD, Clinic of Neurological Diseases, Sofia, Bulgaria
Contact: Study coordinator (PI Prof. Latchezar Traykov)Neurologie Berlin, Berlin, Germany
Contact: Study coordinator (PI Dr. Marie Perle Brinckmann)Universitaetsklinikum Carl Gustav Carus, Dresden, Germany
Contact: Study coordinator (Prof. Björn Falkenburger)Centrum Medyczne NEUROMED, Bydgoszcz, Poland
Contact: Study coordinator (PI Dr. Pawel Lisewski)Neuro-Care sp. z o.o. sp. Komandytowa, Katowice, Poland
Contact: Study coordinator (PI Dr. Gabriela Klodowska)NeuroKlinika Prof. Andrzej Bogucki, Lodz, Poland
Contact: Study coordinator (PI Prof. Andrzej Bogucki)EuroMedis Sp. z o.o., Szczecin, Poland
Contact: Study coordinator (PI Dr. Marcin Ratajczak)Centrum Medyczne NeuroProtect, Warsaw, Poland
Contact: Study coordinator (Dr. Maciej Hyla)Hospital de la Santa Creu i Sant Pau, Unidad de trastornos del movimiento, Barcelona, Spain
Contact: Study coordinator (PI Dr. Javier Pagonabarraga Mora)Hospital General Universitario de Elche, Elche, Spain
Contact: Study coordinator (PI Dr. Eric Freyre Alvarez)Hospital Universitario Ramon y Cajal, Madrid, Spain
Contact: Study coordinator (Jose Lopez Sendon Moreno)